Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH||FF2587 / 3||LA / IM|
Administered by: Private Purchased by: ??
Symptoms: Nasal congestion, Nasopharyngitis, Extra dose administered, Product administered to patient of inappropriate age
Life Threatening? No
Birth Defect? No
Permanent Disability? No
Office Visit (V2.0)? Yes
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Other Medications: N/A
Current Illness: N/A
Preexisting Conditions: N/A
Diagnostic Lab Data:
CDC 'Split Type':
Write-up: Patient is 15 YO female, arrived to clinic with mother for third dose Pfizer on 10/09/2021 at 11:00 am. Patient''s second dose Pfizer was not reviewed and verified by staff. Patient was administered the Pfizer third dose today. Per staff, patient and mother left Clinic with no adverse events. Writer reviewed patient''s prevaccination Checklist for COVID-19 Vaccines and noticed that patient''s age group is not eligible for the booster COVID-19 vaccine at this time. Mother contacted and confirmed that patient''s second dose was administered on 06/12/2021. Mother stated that patient is not experiences any adverse events at this time; however, it appears that patient may be catching a cold. Patient was scheduled with doctor for a post vaccination follow up to address any concerns and questions. Per patient''s visit with doctor, mother stated that patient is experiencing nasal congestion. Writer follow up today and mother stated that patient is doing better and that nasal congestion has improved. Mother instructed to monitor symptoms and follow-up with PCP as needed.
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166